<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Peptide nanotubes &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/peptide-nanotubes/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 10 Oct 2025 15:33:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Peptide nanotubes &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Peptide Nanotubes: A Novel Approach to Overcoming Chemotherapy Resistance</title>
		<link>https://bioengineer.org/peptide-nanotubes-a-novel-approach-to-overcoming-chemotherapy-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 10 Oct 2025 15:33:12 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Nanomedicine]]></category>
		<category><![CDATA[Chemotherapy Resistance]]></category>
		<category><![CDATA[Doxorubicin delivery]]></category>
		<category><![CDATA[Peptide nanotubes]]></category>
		<category><![CDATA[targeted drug delivery]]></category>
		<guid isPermaLink="false">https://bioengineer.org/peptide-nanotubes-a-novel-approach-to-overcoming-chemotherapy-resistance/</guid>

					<description><![CDATA[In a breakthrough that could redefine the landscape of cancer therapeutics, researchers at the Center for Research in Biological Chemistry and Molecular Materials (CiQUS), University of Santiago de Compostela in Spain, have pioneered a novel molecular technique to enhance the intracellular delivery of anticancer drugs. Their focus is on doxorubicin, a cornerstone chemotherapy agent acclaimed [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">278796</post-id>	</item>
	</channel>
</rss>
